GlaxoSmithKline announces partnership with Fiocruz

GlaxoSmithKline has announced a joint venture with Oswaldo Cruz Foundation (Fiocruz), which will see the two organisations working together to develop and manufacture vaccines for conditions including dengue fever.

In a statement, GlaxoSmithKline explained that it will provide Fiocruz with access to the technology behind its 10-valent conjugate vaccine for paediatric pneumococcal disease, which is also known as Synflorix.

Synflorix protects against a range of conditions, including bacteremia, pneumonia, meningitis and otitis media.

Commenting on the move, Abbas Hussain, president of emerging markets at GlaxoSmithKline, said: “This collaboration with Fiocruz is a key piece of our strategy to partner with emerging middle-income countries.”

Jean Stephenne, president and chief executive officer of GlaxoSmithKline Biologicals, stated that the collaboration is the “first step” in an even stronger partnership between the companies.

They have previously collaborated to supply oral polio vaccinations.

In recent days, GlaxoSmithKline announced that it is to work with Amgen to commercialise denosumab in Europe for the management of postmenopausal osteoporosis.